Myasthenia Gravis
Welcome,         Profile    Billing    Logout  
 64 Companies   21 Products   21 Products   23 Mechanisms of Action   207 Trials   10745 News 


«12...2526272829303132333435...136137»
  • ||||||||||  Disparities in Care for Paraneoplastic Neurologic Syndromes (Studio 105 (Sunset Center)) -  Dec 13, 2023 - Abstract #WRMC2024WRMC_709;    
    A major finding was the difference in TTD between PNS, especially anti-NMDA-R encephalitis (Table 1). Perhaps this is due to the newfound notoriety of anti-NMDA-R encephalitis following its media debut, but either way, it provides an example of the efficiency with which PNS can be diagnosed and treated.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal:  A Pilot Study on Tocilizumab in Very-Late-Onset Myasthenia Gravis. (Pubmed Central) -  Dec 13, 2023   
    The results from our study support the efficacy and safety of this combination treatment option for VLOMG, and strongly suggests the therapeutic potential of tocilizumab in VLOMG. However, considering the limitation of retrospective nature and small sample size in this study, prospective randomized controlled studies including a larger sample size of selected patients are needed to validate our results.
  • ||||||||||  Enrollment open:  The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis (clinicaltrials.gov) -  Dec 13, 2023   
    P=N/A,  N=144, Recruiting, 
    However, considering the limitation of retrospective nature and small sample size in this study, prospective randomized controlled studies including a larger sample size of selected patients are needed to validate our results. Not yet recruiting --> Recruiting
  • ||||||||||  Journal:  Editorial: Phenotypes of myasthenia gravis, volume II. (Pubmed Central) -  Dec 11, 2023   
    The precise cut-off values of systemic inflammation response index may be helpful for the surgeon to predict the surgical outcome and post-systemic inflammation response index may be a predictive marker for estimating postoperative treatment changes. No abstract available
  • ||||||||||  Ultomiris (ravulizumab-cwvz) / AstraZeneca
    Review, Journal:  Ravulizumab in Myasthenia Gravis: A Review of the Current Evidence. (Pubmed Central) -  Dec 7, 2023   
    In conclusion, ravulizumab has a simple weight-based administration and long dosing interval. Its targeted mechanism of action without generalized immunosuppression is reflected in its rapid onset of symptom improvement, sustained efficacy and good safety profile in the treatment of patients with anti-AChR antibody-positive gMG.
  • ||||||||||  Review, Journal:  Programming of metabolic and autoimmune diseases in canine and feline: linkage to the gut microbiome. (Pubmed Central) -  Dec 6, 2023   
    Notably, the composition, abundance, activity, and metabolites of the gut microbiome are all elements that shape clinical outcomes concerning metabolism and immune function. This review highlights the implications of the gut microbiome for metabolic disorders (obesity, diabetes, and hepatic lipidosis) and autoimmune diseases (inflammatory bowel disease, osteoarthritis, asthma, and myasthenia gravis) in canine and feline animals, providing novel strategies and therapeutic targets for the prevention and treatment of pet diseases.
  • ||||||||||  Tyvyt (sintilimab) / Innovent Biologics, Eli Lilly
    Review, Journal, Adverse events, Checkpoint inhibition:  A Case Report and Literature Review on Respiratory Failure with Immune Checkpoint Inhibitors: A Life-Threatening Adverse Event. (Pubmed Central) -  Dec 6, 2023   
    Here, a case of 51-year-old male lung cancer patient with sintilimab-associated myasthenia gravis, myositis, and myocarditis overlap syndrome involving the diaphragm who developed severe type II respiratory failure was reported...The potential mechanisms of respiratory failure caused by ICI-associated diaphragmatic dysfunction may be related to T cell-mediated immune disturbances and we proposed possible diagnostic processes. For patients with unexplained respiratory failure who are receiving immunotherapy, standardized diagnostic strategies should be implemented immediately on admission before deciding whether to conduct a more invasive diagnostic procedure or empirical treatment.
  • ||||||||||  Trial completion:  Exploring Accessible Beauty for Individuals With Upper Extremity Deficits (clinicaltrials.gov) -  Dec 6, 2023   
    P=N/A,  N=57, Completed, 
    For patients with unexplained respiratory failure who are receiving immunotherapy, standardized diagnostic strategies should be implemented immediately on admission before deciding whether to conduct a more invasive diagnostic procedure or empirical treatment. Recruiting --> Completed
  • ||||||||||  Tai'ai (telitacicept) / Rongchang Pharma
    Biomarker, New trial:  Exploring the efficacy and biomarkers in the treatment of myasthenia gravis with Telitacicept (EUDRACT) -  Dec 5, 2023   
    P=N/A,  N=60, Not yet recruiting, 
    In conclusion, this study's findings suggest that EV-mediated delivery of caspase-1 inhibitors is effective for treating myasthenia gravis and is promising for clinical applications. .
  • ||||||||||  Review, Journal:  Myasthenia gravis: Molecular mechanisms and promising therapeutic strategies. (Pubmed Central) -  Dec 4, 2023   
    In addition, this review emphasises that combined therapy may have better therapeutic effects and reducing the risk of side effects of treatments, which has great prospects for the treatment of MG. With the deepening of research on immunotherapy targets in MG, novel opportunities and challenges in the treatment of MG will be introduced.
  • ||||||||||  mycophenolate mofetil / Generic mfg.
    Journal, Checkpoint inhibition:  Safety and efficacy of immune checkpoint inhibitor cancer therapy in patients with preexisting type 1 diabetes mellitus. (Pubmed Central) -  Dec 3, 2023   
    All three cases had interruption of ICI therapy and administration of adjunct therapies, including steroids, IVIG, or mycophenolate mofetil with resolution of the IRAE...These data suggest that ICI monotherapy can successfully be used in patients with preexisting T1DM, with IRAE rates comparable with individuals without preexisting T1DM. Larger, prospective studies of these potentially life-saving ICI therapies that include patients with preexisting autoimmunity are warranted.
  • ||||||||||  Review, Journal:  Efficacy and safety of the innovative monoclonal antibodies in adults with generalized myasthenia gravis: a Bayesian network analysis. (Pubmed Central) -  Dec 3, 2023   
    For QMG score, batoclimab 340mg (MD ranged from 4.32 to 8.52) and batoclimab 680mg (MD ranged from 4.11 to 9.31) were more effective than placebo and other monoclonal antibodies except for rozanolixzumab, with the highest SUCRA value (93% and 97% respectively)...Given the limitations inherent in indirect comparisons, further head-to-head and extensive observational studies are necessary to confirm our findings. https://inplasy.com/?s=202370112, identifier 202370112.
  • ||||||||||  Xolair (omalizumab) / Roche, Novartis, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
    Journal:  Management of Autoimmune urticaria in a patient with Myasthenia Gravis, a challenging case. (Pubmed Central) -  Nov 30, 2023   
    Recognition of aiCSU endotype is essential as it helps predict disease course and response to treatment. Moreover, careful therapeutic interventions in patients with CSU and coexistent autoimmune diseases are warranted to achieve efficacy and reduce drug interactions and adverse effects.
  • ||||||||||  azathioprine / Generic mfg.
    Journal:  Primary Thymic Hodgkin Lymphoma Coexisting with Thymoma and Myasthenia Gravis: A Case Report. (Pubmed Central) -  Nov 29, 2023   
    Following investigations, myasthenia gravis was diagnosed and managed by pyridostigmine, prednisolone, and azathioprine...Prior reports revealed regression of myasthenia gravies following Hodgkin lymphoma management, which suggests that myasthenia could be a complication of Hodgkin lymphoma. However, in our case, myasthenia gravis persisted after Hodgkin lymphoma management; therefore, further studies are needed to explore this association.
  • ||||||||||  Journal:  Stability monitoring of patients with myasthenia gravis using a mobile-based application. (Pubmed Central) -  Nov 28, 2023   
    Findings in the juvenile myasthenia gravis group demonstrate the impact of pubertal development and the need for timely and appropriate active therapy, including thymectomy, to improve prognosis. The usability evaluation showed that neurologists evaluated the application at a good level with the average score of 8.23
  • ||||||||||  Review, Journal, CAR T-Cell Therapy:  CAR T cells for treating autoimmune diseases. (Pubmed Central) -  Nov 28, 2023   
    Furthermore, in preclinical models, researchers have also developed chimeric autoantibody receptor T cells that can eliminate individual B cell clones producing specific autoantibodies, and regulatory CAR T cells that do not eliminate autoreactive immune cells but dampen their wrong activation. Finally, we will address safety and manufacturing aspects for CAR T cells and discuss mRNA technologies and automation concepts for ensuring the future availability of safe and efficient CAR T cell products.
  • ||||||||||  Zilbrysq (zilucoplan) / UCB
    Trial initiation date:  A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis (clinicaltrials.gov) -  Nov 27, 2023   
    P2/3,  N=8, Not yet recruiting, 
    Finally, we will address safety and manufacturing aspects for CAR T cells and discuss mRNA technologies and automation concepts for ensuring the future availability of safe and efficient CAR T cell products. Initiation date: Sep 2023 --> Jan 2024
  • ||||||||||  Journal:  A pilot study of an integrated, personalized, respiratory and (Pubmed Central) -  Nov 27, 2023   
    Our telerehabilitation program was feasible, safe, and possibly effective for this pilot cohort of stable pediatric patients with hereditary NMDs. Larger-scale studies for longer periods are warranted to confirm the results.
  • ||||||||||  Review, Journal:  Neurological pathologies in acute acquired comitant esotropia. (Pubmed Central) -  Nov 27, 2023   
    However, AACE can be associated with neurological disorders that require neuroimaging probes. The author recommends that clinicians should perform comprehensive neurological assessments to rule out neurological pathologies in AACE, especially in the presence of nystagmus or abnormal ocular and neurological indications (e.g., headache, cerebellar imbalance, weakness, nystagmus, papilloedema, clumsiness, and poor motor coordination).
  • ||||||||||  pyridostigmine Bromide / Generic mfg.
    Journal:  Facial-onset sensory and motor neuronopathy with myasthenia gravis: A case report. (Pubmed Central) -  Nov 25, 2023   
    Therefore, we reported a rare case in which the 2 conditions concurrently existed. Immune dysfunction might be the pathogenesis of this association, while there is no definite evidence to support it, further studies are needed.